ES2174921T3 - Inhibidores de la proteasa del vih. - Google Patents

Inhibidores de la proteasa del vih.

Info

Publication number
ES2174921T3
ES2174921T3 ES95905886T ES95905886T ES2174921T3 ES 2174921 T3 ES2174921 T3 ES 2174921T3 ES 95905886 T ES95905886 T ES 95905886T ES 95905886 T ES95905886 T ES 95905886T ES 2174921 T3 ES2174921 T3 ES 2174921T3
Authority
ES
Spain
Prior art keywords
treatment
hiv protease
compounds
protease inhibitors
aids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95905886T
Other languages
English (en)
Inventor
Joel R Huff
Joseph P Vacca
Bruce D Dorsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2174921T3 publication Critical patent/ES2174921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) QUE SON INHIBIDORES DE LA PROTEASA DEL VIH. ESTOS COMPUESTOS SON UTILES EN LA PREVENCION O EL TRATAMIENTO DE INFECCIONES POR VIH Y EN EL TRATAMIENTO DEL SIDA, TANTO COMO COMPUESTOS, SALES FARMACOLOGICAMENTE ACEPTABLES, INGREDIENTES PARA COMPOSICIONES FARMACEUTICAS, COMBINADOS O NO CON OTROS AGENTES ANTIVIRALES, INMUNOMODULADORES, ANTIBIOTICOS O VACUNAS. TAMBIEN SE DESCRIBEN METODOS PARA EL TRATAMIENTO DEL SIDA Y METODOS PARA EVITAR O TRATAR LAS INFECCIONES POR VIH.
ES95905886T 1993-12-15 1994-12-12 Inhibidores de la proteasa del vih. Expired - Lifetime ES2174921T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16801393A 1993-12-15 1993-12-15
US17047593A 1993-12-20 1993-12-20

Publications (1)

Publication Number Publication Date
ES2174921T3 true ES2174921T3 (es) 2002-11-16

Family

ID=26863718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95905886T Expired - Lifetime ES2174921T3 (es) 1993-12-15 1994-12-12 Inhibidores de la proteasa del vih.

Country Status (19)

Country Link
US (2) US5646148A (es)
EP (1) EP0734387B1 (es)
JP (1) JP3000564B2 (es)
KR (1) KR100234863B1 (es)
CN (1) CN1046727C (es)
AT (1) ATE215952T1 (es)
AU (1) AU692509B2 (es)
BG (1) BG62093B1 (es)
BR (1) BR9408305A (es)
CA (1) CA2178760C (es)
CZ (1) CZ288312B6 (es)
DE (1) DE69430385T2 (es)
ES (1) ES2174921T3 (es)
FI (1) FI962488A0 (es)
HU (1) HUT74681A (es)
NZ (1) NZ278201A (es)
PL (1) PL314984A1 (es)
SK (1) SK75796A3 (es)
WO (1) WO1995016688A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7508196A (en) 1995-11-13 1997-06-05 Gerard Voerman Anti-viral isolates obtainable from leeches
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
TW438799B (en) * 1997-05-29 2001-06-07 Merck & Co Inc HIV protease inhibitor
JP3472261B2 (ja) * 1997-08-25 2003-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ネビラピン半水化物を含有する医薬用懸濁液
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
CO4970782A1 (es) * 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
FR2780649B1 (fr) 1998-07-06 2001-03-09 Univ Paris Vii Denis Diderot Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
GB2341385A (en) 1998-09-14 2000-03-15 Merck & Co Inc Recovery of iodide from chemical process waste water
US6440946B1 (en) * 1999-02-25 2002-08-27 Takeda Chemical Industries, Ltd. Multiple-agents-binding compound, production and use thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
WO2001038332A1 (en) * 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
US6482952B2 (en) 2000-06-20 2002-11-19 Merck & Co., Inc. Process for preparing acetonides
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
AU2003270727A1 (en) * 2002-09-17 2004-04-08 Luna Innovations, Inc. Remote temperature sensing of small volume and related apparatus thereof
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
ATE163926T1 (de) * 1991-11-08 1998-03-15 Merck & Co Inc Hiv-protease-inhibitoren verwendbar in der aids- behandlung
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CZ286412B6 (en) * 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation

Also Published As

Publication number Publication date
CN1142827A (zh) 1997-02-12
SK75796A3 (en) 1997-05-07
BG62093B1 (bg) 1999-02-26
FI962488A7 (fi) 1996-06-14
JPH09506619A (ja) 1997-06-30
EP0734387A1 (en) 1996-10-02
FI962488L (fi) 1996-06-14
HU9601649D0 (en) 1996-08-28
FI962488A0 (fi) 1996-06-14
AU1433195A (en) 1995-07-03
EP0734387B1 (en) 2002-04-10
JP3000564B2 (ja) 2000-01-17
CZ158696A3 (en) 1996-11-13
BG100643A (bg) 1997-02-28
NZ278201A (en) 1998-01-26
ATE215952T1 (de) 2002-04-15
DE69430385D1 (de) 2002-05-16
CN1046727C (zh) 1999-11-24
AU692509B2 (en) 1998-06-11
CA2178760C (en) 2000-08-01
HUT74681A (en) 1997-01-28
US5807841A (en) 1998-09-15
DE69430385T2 (de) 2002-11-07
WO1995016688A1 (en) 1995-06-22
BR9408305A (pt) 1997-08-26
EP0734387A4 (en) 1997-03-05
KR100234863B1 (ko) 1999-12-15
CZ288312B6 (en) 2001-05-16
PL314984A1 (en) 1996-09-30
CA2178760A1 (en) 1995-06-22
US5646148A (en) 1997-07-08

Similar Documents

Publication Publication Date Title
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
ES2181725T3 (es) Inhibidores de hiv proteasa.
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2112880T3 (es) Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
ES2132201T3 (es) Inhibidores de la hiv proteasa utiles en el tratamiento del sida.
EA200000594A1 (ru) Новые макролиды
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
ES2176263T3 (es) 5,6-dihidropironas derivadas como inhibidores de proteasa y agentes antivirus.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
EA200001029A1 (ru) Производные гигромицина
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
AR013758A1 (es) Terapia de combinacion para el tratamiento de sida.
ES2191035T3 (es) Derivados de la pirona como inhibidores de la proteasa y agentes antiviricos.
MX9701121A (es) Combinacion inhibidora de proteasa de vih.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734387

Country of ref document: ES